RISVUTATUG REZETECAN
UNII 7T9A6CKG67

Substance Identification & Data

This profile provides standardized clinical and technical data for Risvutatug Rezetecan, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 7T9A6CKG67.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3042849-33-9 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

7T9A6CKG67

CAS Registry Number

3042849-33-9

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

RISVUTATUG REZETECAN

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C187121

National Cancer Institute reference terminology for clinical and research data.

INN ID

13784

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Risvutatug Rezetecan

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Risvutatug Rezetecan. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Risvutatug Rezetecan

Common Names & Synonyms

H-gamma1 heavy chain Homo sapiens (1-449) [VH (Homo sapiens IGHV3-30*01 (94.9%) -(IGHD) -IGHJ4*01 (92.9%) T122>A (113), CDR-IMGT [8.8.12] (26-33.51-58.97-108)) (1-119) -Homo sapiens IGHG1*01 (100%) G1m17,1 CH1 K120, CH3 D12, L14 (CH1 K120 (216) (120-217), hinge 1-15 (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS (448-449)) (120-449)], (222-215')-disulfide with L-lambda1 light chain Homo sapiens (1'-215') [V-LAMBDA (Homo sapiens IGLV8-61*01 (89.7%) -IGLJ3*02 (100%), CDR-IMGT [9.3.10] (26'-34'.52'-54'.91'-100')) (1'-110') -Homo sapiens IGLC1*02 (100%) (C-LAMBDA1 S127>del) (111'-215')]; dimer (228-228'':231-231'')-bisdisulfide; produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa; substituted at the sulfur atoms of four L-cysteinyl residues on an average among 222, 228, 231, 215', 222'', 228'', 231'' and 215''' with (3RS)-1-[(2R,10S)-10-benzyl-2-cyclopropyl-1-{[(1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl]amino}-1,6,9,12,15,18-hexaoxo-3-oxa-5,8,11,14,17-pentaazatricosan-23-yl]-2,5-dioxopyrrolidin-3-yl (rezetecan) groups

Immunoglobulin G1, anti-(human B7 homolog protein B7H3) (human monoclonal GSK5764224 γ-chain), disulfide with [de-C-terminal-serine] human monoclonal GSK5764224 λ-chain, dimer, reduced, 215′′,222,228,231′-tetrakis(thioether) with N-[6-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-1-oxohexyl]glycylglycyl-L-phenylalanyl-N-[[(1R)-1-cyclopropyl-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-2-oxoethoxy]methyl]glycinamide

immunoglobulin G1-lambda1, anti-[Homo sapiens CD276 (B7H3, B7-H3, B7-related protein 2, B7RP2, B7RP-2, B7 homolog 3, B7 homologue 3)], Homo sapiens monoclonal antibody; conjugated on an average of four cysteinyl residues to rezetecan, comprising a linker and a camptothecin derivative (exatecan) (risvutatug rezetecan)

risvutatug rezetecan [INN]

External Clinical & Regulatory Resources

Previous UNII7T97M7E6E7

Next UNII7T9FYH5QMK